Reports on NLR and PLR as follow-up markers during systemic therapy for psoriasis vulgaris are to date mostly limited to TNF-α inhibitors (etanercept, infliximab, adalimumab [27–29]) or the IL-12/23 inhibitor ustekinumab [27–29], with little data on anti-IL-17A therapy (brodalumab [30], secukinumab, ixekizumab [29]) and IL-23 inhibitors [31]. Here, IL37 is linked to psoriasis vulgaris.